News from second genome A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 24, 2022, 15:15 ET Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented...

Apr 08, 2022, 13:00 ET Second Genome Presents New Preclinical Data at AACR 2022 Demonstrating that SG-3-06686, a CXCR3 Chemokine Receptor Modulator, Induces Migration of Immune Effector Cells, Inhibits Tumor Growth as Monotherapy and Boosts Anti-Programmed Death Protein-1 (PD-1) Activity

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented...

Mar 02, 2022, 07:00 ET Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced...

Feb 24, 2022, 07:00 ET Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, yesterday...

Feb 18, 2022, 12:30 ET Second Genome Presents New Preclinical Data for SG-5-00455, Potential First-in-Class Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD), at the 17th Congress of European Crohn's and Colitis Organization (ECCO)

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today...

Feb 14, 2022, 07:00 ET Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today...

Feb 10, 2022, 07:00 ET Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today...

Jan 19, 2022, 07:00 ET Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers from public ...

Dec 20, 2021, 07:00 ET Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers...

Nov 18, 2021, 17:18 ET Second Genome Presents Preclinical Data at Crohn's & Colitis Foundation's® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers,...

Nov 12, 2021, 07:00 ET Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers,...

Nov 11, 2021, 07:00 ET Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson's Disease at The Society for Neuroscience Annual Meeting

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers,...

Oct 07, 2021, 07:00 ET Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers,...

Sep 23, 2021, 07:00 ET Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers,...

Sep 16, 2021, 07:00 ET Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers...

Aug 23, 2021, 07:00 ET Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company's Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers...

Aug 10, 2021, 07:00 ET Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers...

Aug 05, 2021, 07:00 ET Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers

Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight to discover and develop precision therapies and biomarkers...

Jun 22, 2021, 07:00 ET Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD)

Second Genome, a biotechnology company that leverages its proprietary platform sg-4-sight and AI workflows to discover and develop precision...

Jun 09, 2021, 07:00 ET Second Genome to Present Big Data Analytics Capabilities at the Microbiome Data Congress

Second Genome, a tech-enabled biotechnology company that extracts microbial genetic insights to make transformational precision therapies and...

Apr 15, 2021, 07:00 ET Second Genome to Present at the Jefferies Microbiome-Based Therapeutics Summit

Second Genome, a tech-enabled biotechnology company that extracts microbial genetic insights to make transformational precision therapies and...

Jan 25, 2021, 09:00 ET Second Genome Appoints Dr. Susannah Cantrell to Chief Business Officer and Dr. Preeti Gupta Lal to Chief Scientific Officer

Second Genome, a leader in microbiome science, today announced the appointment of Susannah Cantrell, PhD, to the position of chief business officer,...

Jan 19, 2021, 07:00 ET Second Genome To Present Biomarker Data in Oncology at Keystone Symposium

Second Genome, a leader in microbiome science, will present data today demonstrating the identification of a microbiome-based composite biomarker...

Jan 11, 2021, 07:00 ET Second Genome To Present at Biotech Showcase Digital 2021 Conference

Second Genome, a leader in microbiome science, today announced that the company is presenting at the 13th Annual Biotech Showcase Digital 2021...

Sep 26, 2018, 08:00 ET Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer

Second Genome, Inc., a clinical-stage company focused on the development of novel therapeutics identified through microbiome science, today announced ...